Given the co‐expression of both BCL‐2 and MCL‐1 in subsets of NHL such as MCL [18], we hypothesized that simultaneous targeting of these proteins would afford increased efficacy in this disease. The gene discussed is BCL2; the disease is non-Hodgkin lymphoma.